The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral.

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
Advertisements

© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
© 2010, American Heart Association. All rights reserved. Evolving Patterns of Use and Appropriateness of Aldosterone Antagonists in Heart Failure Nancy.
Associations Between Outpatient Heart Failure Process of Care Measures and Mortality Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade,
Hernandez et al. JAMA, May 5, 2010 – Vol. 303, No. 17 Relationship Between Early Physician Follow-up and 30-day Readmission Among Medicare Beneficiaries.
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
IntroductionMethods (continued)Results (continued)Strengths and Limitations Background Pharmacologic treatments are efficacious in reducing post-myocardial.
DISCLOSURE INFORMATION (relative only): Eric D. Peterson, PI of the AHA GWTG Data Analysis Center; Lee H. Schwamm, Chair of the AHA National Steering Committee.
Schneider Institute for Health Policy, The Heller School for Social Policy and Management, Brandeis University The Effects of the Hospital Quality Incentive.
Kelley M. Anderson, PhD, FNP
“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,
Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
Cohen et al. Circulation. ePub May 17, 2010 Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction Findings From Get With The Guidelines.
Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes: An Analysis from the Get With The Guidelines Program.
0 Hospital Quality Incentive Demonstration (HQID) Key Facts Three year demo ( ); extended for three additional years through Oct hospitals.
Evolving Patterns Of Use Of Aldosterone Inhibition In Chronic Heart Failure; A Report From Get With The Guidelines HF Nancy M. Albert, Clyde W. Yancy,
Schneider Institute for Health Policy, The Heller School for Social Policy and Management, Brandeis University The Relationship between Performance on.
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained Over Time? A Longitudinal Comparison of GWTG-CAD.
Use of Hydralazine-Isosorbide Dinitrate combination in African American and Other Race/Ethnic Group Patients with Heart Failure and Reduced Ejection Fraction.
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines– Coronary.
“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768  777. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized.
Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Patients with HF have increased risk for thrombotic events. However, the net clinical benefit of anticoagulation in a HF population in sinus rhythm has.
Schwamm et al. Circulation epub April 6Schwamm et al. Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke Lee H. Schwamm, MD; Mathew.
Practical Examples. Presenter disclosure information Bradley G Hammill Lesley H Curtis Soko Setoguchi Practical Examples FINANCIAL DISCLOSURE: None UNLABELED/UNAPPROVED.
Demonstration of a Process- Outcome Link for Smoking Cessation Melissa M. Farmer, PhD 1,2 Elizabeth M. Yano, PhD 1,2 Brian S. Mittman, PhD 1,2 Scott E.
Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients: Results From the AHA’s Get With the Guidelines Program Todd M. Brown,
Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation Zubin J. Eapen, Xiaojuan.
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
Influence of Age on the Management of Heart Failure: Findings from Get With the Guidelines-HF DE Forman, CP Cannon, AF Hernandez, L Liang, CW Yancy, GC.
ACUTE MYOCARDIAL INFARCTION Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Emergency Medical Services Hospital Departments:
Heart Failure JCAHO Core Measure Project Heart Failure Core Measure Team.
” “The Dissociation Between Door-to- Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes”
Do Heart Failure Disease Management Programs Make Financial Sense Under a Bundled Payment System? Zubin J. Eapen, Shelby D. Reed, Lesley H. Curtis, Adrian.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
The IC 3 (Improving Continuous Cardiac Care) - PINNACLE Program: A Report of the first 14,000+ Patients Paul S. Chan, MD MScWilliam J. Oetgen, MD Donna.
Background Current guideline recommend an early invasive strategy for NSTEMI patients (Class IIA). However, 67% US hospitals have no catheterization capability.
Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz RRT, MS, Administrative.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Quality of Care in Physician Groups Do Larger Integrated Systems Deliver Higher Quality Care? Ateev Mehrotra MD MPH RAND Pittsburgh & University of Pittsburgh.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Acknowledgements Contact Information Anthony Wong, MTech 1, Senthil K. Nachimuthu, MD 1, Peter J. Haug, MD 1,2 Patterns and Rules  Vital signs medoids.
Assessing Inpatient Care Using Hospital Quality Alliance Patient Level Quality Data What can we learn about inpatient care quality from patient-level data.
Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,
Disparities in Inpatient Quality of Care Measures by Race and Ethnicity ____________________________ Academy Health June 27, 2005 Boston, MA Romana Hasnain-Wynia,
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Comparing the Effectiveness of Carotid Stent Systems versus Endarterectomy Peter W. Groeneveld, MD, MS Assistant Professor of Medicine Philadelphia Veterans.
HEART FAILURE Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Nursing, QRM, CCE, Medical Records Project Coordinators: Carmen.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.
HEART FAILURE TEAM MEMBERSHIP DEPARTMENTS OF CARDIOLOGY, CARDIOVASCULAR SURGERY, MEDICINE, NURSING, QUALITY AND RESOURCE MANAGEMENT, THE CENTER FOR CLINICAL.
A Statewide Collaborative Initiative to Improve the Quality of Care for Patients With Acute Myocardial Infarction and Heart Failure Circulation. 2009;119:
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure: A Report From the OPTIMIZE-HF Registry.
Copyright © 2007 American Medical Association. All rights reserved.
HEART FAILURE TEAM MEMBERSHIP
Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From.
Step Care Therapy for Hypertension in Diabetic Patients
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Fig. 2. Evidence-based medication prescriptions
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Presentation transcript:

The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral Fellow Duke Clinical Research Institute (DCRI)

Acknowledgements n Duke Clinical Research Institute (DCRI) l Lesley Curtis, Ph.D. l Adrian Hernandez, M.D. l Bradley Hammill, M.S. l Kevin Schulman, M.D. l Eric Peterson, M.D. n UCLA Medical Center l Gregg Fonarow, M.D. n Funding Sources l Contract with GlaxoSmithKline l Duke CERTs grant (AHRQ grant #U18HS10548)

Pay-for-Performance and Process Measures n Goal of Pay-for-Performance: Encourage providers to follow recommended clinical care by providing financial incentives n Theory: Financial incentives  improve providers’ adherence  improve clinical outcomes n Process Measures: Estimate provider-level adherence to this recommended clinical care

CMS Heart Failure Process Measures n Improving heart failure care remains a priority for CMS l Prevalence = 5 million; Cost = $30 billion n 4 Core Process Measures l Providing discharge instructions l Conducting left ventricular ejection fraction (LVEF) assessment l Prescribing ACE inhibitors or angiotensin receptor blockers at discharge l Providing smoking cessation counseling

Associations between process measures (PM) and mortality n Mixed evidence in regards to the associations between process measures and mortality l Acute coronary syndrome 1 l AMI 2 l Heart failure 3 n No evidence in regards to associations between PM and long-term mortality 1: Peterson et al., JAMA, Bradley et al., JAMA, Fonarow et al., JAMA, : Peterson et al., JAMA, Bradley et al., JAMA, Fonarow et al., JAMA, 2007

Objective n Measure associations between the 4 current CMS heart-failure process measures and 1-year mortality l H 1 : Hospital-level process measures will be associated with patient-level mortality

Data Sources n Retrospective cohort study n Matched HF patients within the OPTIMIZE registry with their Medicare Part A claims (2003 – 2004 l OPTIMIZE-HF l Medicare Part A l CMS denominator files n Matched on age, gender, discharge date, and hospital

Participants n Medicare fee-for-service HF patients matched to the OPTIMIZE-HF registry (N=22,483) n Excluding patients who died before discharge n Excluding hospitals with l missing process measures l with less than 25 patients n Final analytic dataset (N=22,451)

Hospital-level single process measures (PM) n Discharge instructions N=15,142 (67%) n LVEF assessment N=20,061 (89%) n ACEI or ARBs at discharge N=5,457 (24%) n Smoking cessation at discharge N=902 (4%) Frequency of PM documentation Number of patients eligible to receive PM

Hospital-level combined process measures n Composite N=22,451 Total number of processes documented Total number of opportunities to perform n Defect-free N=22,451 Proportion of patients within the hospital having documentation for ALL the PM that they were eligible to receive

Outcome and Control Variables n Patient-level Mortality l CMS denominator file n Patient-level controls l Demographics l Comorbities l Clinical measures Creatinine, weight, blood pressure n Hospital-level volume l Total HF discharges l % HF discharges of total

Statistical Analysis n Cox multivariate regressions l Controlling for demographics, clinical measures, selected co-morbidities, and hospital volume indicators l Accounting for clustering of patients within hospitals n 6 final models l 4 Models for each single PM l 2 Models for each combined PM

Selected Baseline Characteristics (N=22,451) Variable% Mean age (s.d) 79 (7.8) Male44% White84% Black10% Other6% Prior AMI 23% Prior PVD 15% Prior Hyperlipidemia 33% Mean Serum Creatinine (mg/dL) (s.d) 1.6 (1.2) Mean Systolic BP (mmHg) (s.d) 142 (32) Mean Weight (kg) (s.d) 77.4 (20.8)

Hospital PM Adherence Rates (N=178) Process Measure (PM) Mean Score S.D.Range Single Discharge Instructions (0 – 1.0) LVEF Assessment (0.29 – 1.0) ACEI / ARBs at Discharge (0.25 – 1.0) Smoking Cessation (0 – 1.0) Combined Composite (0.32 – 1.0) Defect-free (0 – 1.0)

Associations between hospital-level process measures and patient mortality HR (95 % CI) Process Measure (PM) NUnadjustedAdjusted Single Discharge Instructions 15, (0.99 – 1.02) 0.99 (0.98 – 1.01) LVEF Assessment 20, (0.96 – 1.04) 1.0 (0.96 – 1.03) ACEI / ARBs at Discharge 5, (0.89 – 0.99) 0.97 (0.93 – 1.02) Smoking Cessation (0.96 – 1.03) 0.98 (0.93 – 1.04) Combined Composite22, (0.99 – 1.03) 1.0 (0.98 – 1.01) Defect-free22, (0.99 – 1.03) 1.0 (0.99 – 1.01)

Discussion n Current CMS heart failure process measures (PM) are not associated with 1-year mortality in Medicare beneficiaries diagnosed with HF n Explanation for null findings l Care given at discharge may not affect 1-year mortality l Documentation of care does not capture the intensity or accuracy of care l High variation for PM may prevent ability to detect small changes if they exist

Limitations n Cross-sectional design n Unobserved factors confounding associations l Patient-level l Hospital-level n Documentation of process measure at discharge may not reflect the care given over 1 year

Strengths n First known study to link clinical registry data with CMS data to examine associations between process measures and long-term outcomes n Generalizeable to Medicare fee-for-service heart failure patients n Generalizeable to Medicare fee-for-service heart failure patients 1 n n Models l l Include both patient and hospital-level covariates l l Account for clustering 1: Curtis et al., Abstract Proceedings at AHA, 2007

Conclusions & Recommendations n Null findings do not undermine the need to continue providing care that is good clinical practice n Need to more firmly establish link between PM and outcomes before broadly implementing P4P n Improve the accuracy of the measures n Continue evaluating the effects of PM l Within the context of longitudinal data l Using PM with known clinical efficacy